ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Antibiotics"

  • Abstract Number: 192 • 2020 Pediatric Rheumatology Symposium

    Single Center Consensus of Prophylactic Treatment in Immunocompromised Children with Rheumatic Disease

    Stephen Wong1, Amy Gaultney 2 and Deborah McCurdy 3, 1University of California Los Angeles, Los Angeles, California, 2UCLA, Los Angeles, California, 3UCLA Medical Center, Los Angeles, California

    Background/Purpose: Many children with rheumatic diseases require immunosuppressive treatments, however these medications put them at risk for contracting opportunistic infections leading to severe morbidity and…
  • Abstract Number: 1220 • 2018 ACR/ARHP Annual Meeting

    The Impact of Gender on the Clinical Presentation, Management and Outcomes of Patients with Native Joint Septic Arthritis

    Lior Nissim1, Mary Louise Fowler2, Robert Shmerling3, Sarah Lieber4, Mohammad Naffaa5 and Ziv Paz4,5, 1Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel, 2Boston University School of Medicine, Boston, MA, 3Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, 4Beth Israel Deaconess Medical Center, Boston, MA, 5Galilee Medical Center, Nahariya, Israel

    Background/Purpose: Approximately 20,000 cases of septic arthritis (SA) occur in the United States each year with 2-10 cases per 100,000 person-years in the general population.…
  • Abstract Number: 1238 • 2018 ACR/ARHP Annual Meeting

    The Effect of Antibiotic Therapy on Positive Culture Results Among Patients with Prosthetic Joint Septic Arthritis

    Efrat Gur Rosset1, Mary Louise Fowler2, Sarah Lieber3, Robert Shmerling4 and Ziv Paz3,5,6, 1Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel, 2Boston University School of Medicine, Boston, MA, 3Beth Israel Deaconess Medical Center, Boston, MA, 4Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, 5Galilee Medical Center, Nahariya, Israel, 6Azrieli Faculty of Medicine, Bar-Ilan University, Sefad, Israel

    Background/Purpose: Little is known about the effects of antibiotic therapy on synovial and blood culture results among patients with prosthetic joint septic arthritis (PJSA). In…
  • Abstract Number: 1915 • 2016 ACR/ARHP Annual Meeting

    Partial Elimination of Intestinal Microbiota Dampens T Helper 17 Cell Differentiation and Established Collagen-Induced Arthritis in Mice

    Rebecca Rogier1, Heather Evans-Marin2, Birgitte Walgreen1, Monique M. Helsen1, Liduine van den Bersselaar1, Peter M. van der Kraan1, Fons A.J. van de Loo3, Peter L. van Lent1, Jose U. Scher4, Wim B. van den Berg1, Marije I. Koenders1 and Shahla Abdolahi-Roodsaz1, 1Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 2Division of Rheumatology, New York University School of Medicine, New York, NY, 3Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 4New York University School of Medicine, New York, NY

    Background/Purpose: High-throughput sequencing of intestinal microbiota recently revealed that the composition of intestinal microbiota is perturbed in patients with new onset untreated rheumatoid arthritis (RA).…
  • Abstract Number: 1345 • 2015 ACR/ARHP Annual Meeting

    The Impact of Prior Antibiotic Treatment on Culture Results of Patients with Septic Arthritis

    Ziv Paz1, Sarah B. Lieber1, Andrew Moore2, Clara Zhu3, Mary Louise Fowler4 and Robert H. Shmerling5, 1Beth Israel Deaconess Medical Center, Boston, MA, 2Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, 3Medical School, Boston University School of Medicine, Boston, MA, 4School of Medicine, Boston University School of Medicine, Boston, MA, 5Medicine, Beth Israel Deaconess Medical Center, Boston, MA

    Background/Purpose: Synovial fluid culture and gram stain offer the most compelling proof of septic arthritis (SA); these tests are indicated in every suspected case. However,…
  • Abstract Number: 1927 • 2015 ACR/ARHP Annual Meeting

    Salinomycin Induces Potent Suppression of TGF-β1-Mediated Expression of Profibrotic Genes in Cultured Dermal Fibroblasts from Normal Donors and from Donors with Systemic Sclerosis (SSc): A Novel Anti-Fibrotic Treatment for Tissue Fibrosis in SSc

    Peter J. Wermuth1 and Sergio A. Jimenez2, 1Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, 2Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA

    Background/Purpose: Activated myofibroblasts are the primary mediators of the excessive synthesis and deposition of collagens and other extracellular matrix (ECM) macromolecules during the pathogenesis of…
  • Abstract Number: 2823 • 2015 ACR/ARHP Annual Meeting

    Gut Inflammation in HLA-B27 Transgenic Rats Alters the Monocyte Compartment and Its Osteoclastogenic Potential

    C. Ansalone, L. Utriainen, S. W. F. Milling and C. S. Goodyear, Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Human HLA-B27 and β2-microglobulin transgenic rats (B27 rats), an animal model for spondyloarthropathies, spontaneously develop inflammatory colitis and bone loss. We have previously demonstrated…
  • Abstract Number: 929 • 2014 ACR/ARHP Annual Meeting

    Antibiotic Exposure and the Development of Juvenile Idiopathic Arthritis: A Population-Based Case-Control Study

    Daniel B. Horton1,2, Frank I. Scott IV1,3, Kevin Haynes1, Mary E. Putt1, Carlos D. Rose2, James D. Lewis1,3 and Brian L. Strom1,4, 1Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 2Pediatrics, Division of Rheumatology, Nemours A.I. duPont Hospital for Children, Thomas Jefferson University, Wilmington, DE, 3Medicine, Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA, 4Rutgers Biomedical and Health Sciences, Newark, NJ

    Background/Purpose: Dysregulation of the human microbiome has been implicated in the development of several autoimmune diseases, including rheumatoid arthritis and inflammatory bowel disease (IBD). Moreover,…
  • Abstract Number: 856 • 2014 ACR/ARHP Annual Meeting

    A Pathogenic Role for the Gut Microbiota in Murine Antiphospholipid Syndrome and Lupus

    Silvio M. Vieira1, Andrew Yu1, Michael Hiltesperger1, Odelya E. Pagovich1, Eleni Tiniakou1, William Ruff2, John Sterpka1 and Martin Kriegel2,3, 1Yale School of Medicine, New Haven, CT, 2Immunobiology, Yale School of Medicine, New Haven, CT, 3Medicine, Section of Rheumatology, Yale School of Medicine, New Haven, CT

    Background/Purpose: The etiology of lupus-associated antiphospholipid syndrome (APS) is unknown but microbial triggers have been implicated in transient antiphospholipid antibody production in both mice and…
  • Abstract Number: 2740 • 2014 ACR/ARHP Annual Meeting

    Microbiota Modulate Intraepithelial Lymphocyte Presence and Function

    Kristine A. Kuhn and Sean P. Colgan, University of Colorado School of Medicine, Aurora, CO

    Background/Purpose: Microbiome studies in autoimmune diseases including rheumatoid arthritis and inflammatory bowel disease demonstrate alterations in relative abundance of specific bacterial species (dysbiosis). The immunologic…
  • Abstract Number: 2807 • 2013 ACR/ARHP Annual Meeting

    Management Of Vertebral Osteomyelitis: A Randomized Clinical Trial Comparing 6 Versus 12 Weeks Of Antibiotic Treatment

    Louis Bernard1, Aurélien Dinh2, Idir Ghout3, Valérie Zeller4, Bertrand Issartel5, Nadia Belmatoug6, Michel Dupon7 and Denis Mulleman8, 1University hospital of Tours, Tours, France, 2University hospital of Paris, Garches, France, 3Biostatistic, University Hospital of Paris, Boulogne, France, 4Internal medicine, La Croix Saint Simon Hospital, Paris, France, 5Clinique du Tonkin, Lyon, France, 6University hospital of Paris, Clichy, France, 7infectious disease, University Hospital of Bordeaux, Bordeaux, France, 8CHU Trousseau Tours, Tours, France

    Background/Purpose: As for most of bone and joint infection, optimal treatment duration for vertebral osteomyelitis (VO) is unknown. In an era of increasing bacterial resistance,…
  • Abstract Number: 556 • 2013 ACR/ARHP Annual Meeting

    Depletion Of The Gut Microbiota Prevents β2-Glycoprotein I Antibody Production and Mortality In a Model Of Antiphospholipid Syndrome

    Silvio M. Vieira1, Andrew Yu1, Odelya E. Pagovich1, Eleni Tiniakou2, John Sterpka1 and Martin A. Kriegel3,4, 1Yale School of Medicine, New Haven, CT, 2Yale University School of Medicine, New Haven, CT, 3Immunobiology, Yale School of Medicine, New Haven, CT, 4Medicine/Division of Rheumatology, Yale School of Medicine, New Haven, CT

    Background/Purpose: Infectious triggers have been implicated in transient antiphospholipid antibody production in both mice and humans. The cause of persistent anti-β2-glycoprotein I (β2GPI) antibody production…
  • Abstract Number: 172 • 2012 ACR/ARHP Annual Meeting

    A Systematic Review and Meta-Analysis of Antibiotic Treatment for Reactive Arthritis

    Claire E. Barber1, Joseph Kim2, Robert D. Inman3, John Esdaile4 and Matthew T. James5, 1Rheumatology, University of Calgary, Calgary, AB, Canada, 2Medicine, University of Calgary, Calgary, Canada, 3Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 4Medicine, University of British Columbia, Vancouver, BC, Canada, 5Medicine, Univeristy of Calgary, Calgary, Canada

    Background/Purpose: Although bacterial infections are a common precipitant, it is unclear whether antibiotic treatment is effective for reactive arthritis. The purpose of this study was…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology